Standard BioTools Acquires Sengenics from Summa Equity

Summa Equity Acquires Majority Stake in Sengenics

October 14, 2020

Biotechnology

Summa Equity Fund II has acquired a majority stake in Sengenics, a functional proteomics company that commercialises the KREX technology for full‑length, correctly folded protein production and autoantibody detection. The investment will support Sengenics' product development, global expansion and accelerated commercial adoption across pharma, academic research and diagnostics.

Illumina Acquires SomaLogic from Standard BioTools

January 30, 2026

Biotechnology

Illumina has completed its acquisition of SomaLogic from Standard BioTools for $350 million in cash plus up to $75 million in near-term performance-based payments, adding SomaLogic's proteomics capabilities to Illumina's multiomics strategy. The deal expands Illumina's ability to integrate SomaLogic's SomaScan platform with its NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics to accelerate proteomics at scale while Standard BioTools receives upfront cash, potential earnouts and ongoing royalties.

Sherlock Biosciences Acquires Sense Biodetection

February 1, 2023

Biotechnology

Sherlock Biosciences has acquired Sense Biodetection to accelerate commercialization of CRISPR-enabled, instrument-free molecular diagnostics by integrating Sense’s Veros rapid, instrument-free test platform, chemistry and manufacturing capabilities into Sherlock’s platform. Terms were not disclosed; Sense is headquartered in Oxford, United Kingdom with additional facilities in Cambridge (UK) and Milford, Massachusetts.

SeqOne Acquires Congenica

September 2, 2025

Software

SeqOne has acquired Congenica, a UK clinical genomics software company spun out of the Wellcome Sanger Institute, creating one of the largest pure‑play genomics software firms serving over 160 laboratories in 30+ countries. The combined business will integrate SeqOne's AI-driven NGS analysis platform with Congenica's clinical decision‑support tools to accelerate rare disease diagnoses and personalized cancer therapies while expanding SeqOne's UK presence.

Bionano Genomics Acquires BioDiscovery

October 12, 2021

Software

Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.

Summa Equity Acquires Majority Stake in Axion BioSystems

July 15, 2021

Medical Devices

Summa Equity Fund II has acquired a majority stake in Axion BioSystems, a US life science tools company that develops MEA (microelectrode array) and impedance-based bioelectronic assay technologies. Summa plans to support Axion's commercial scale-up and global growth to accelerate adoption of its platforms across academia and biopharma, particularly in cell and gene therapy and drug discovery applications.